ネクスト/沿革

October 5 1989	Founded as Mic Corp (current, NEXT21) with the capital of 10 million yen.
2000	Executed the joint development agreement of the medical device for interventions, initially self-developed, with TERUMO CORP..
2000	Altered corporate names to NXTK.K., and the increased the capital to 25 million yen.
August 2001	Applied for a patent about Hemostatic and adhesion-preventive biopolymer microscopic particles (Dadd).
February 2002	Applied for a patent about drug administration method (Dadd).
December 2002	Applied for a patent about artificial bone forming method (CT-Bone).
July 2003	Made a joint application for a patent about artificial bone fabrication method by the powder lamination method (CT-Bone) with the Institute of Physical and Chemical Research.
November 2003	Increased the capital of 66,500,000 yen.
March 2004	Received grant for the custom-made artificial bone implant "CT-Bone" and full-size bone model molding service from the UFJ New Frontier Company Development Foundations.
July 2004	Increased the capital to 131,516,000 yen by the allocation of new shares to third parties including two companies of venture capitals, and Mitsubishi Corp.,.
October 2004	Received grant for custom-made bone implant "CT-Bone" from New Energy and Industrial Technology Development Organization (NEDO).
December 2004	Coestablished The 3D Organ Modeling Group for Clinical Applications with Division of Tissue Engineering, the University of Tokyo Hospital.
January 2005	Applied for a patent about bone regeneration system (CT-Bone).
September 2005	Increased the capital to 157,816,000 yen by the allocation of new shares to third party.
January 2006	Applied for a patent about gel-forming composition for medical use, devices for the application of the composition.
January 2006	Started clinical study of CT-Bone in University of Tokyo Hospital, after being approved by the hospital Internal Review Board.
February 2006	Applied for a patent about Process for producing bone grafting material, bone grafting material, three-dimensional support for cell culture, and separation support for chromatography.
March 2006	Increased the capital to 401,566,000 yen by allocation of new shares to third pary.
April 2006	Applied for a patent about figure-forming composition.
May 2006	Received grant for Tetrapod-shaped bone fillers from NEDO.
August 2006	Applied for a patent about bone model and bone fillers (CT-Bone).
August 2006	Applied for a patent about protective agent for oral mucosa containing trehalose.
September 2006	Received grant for costom-made bone implant from National Institute of Biomedical Innovation (NIBIO).
October 2006	Received grant for development of manufacturing technologies of medical devices through sophisticating combined metallic process of optical lithography from Kansai Bureau of Economy, Trade and Industry
October 2006	Received grant for clinical trial on custom-made artificial bone implant from NIBIO.
November 2006	Applied for a patent about bone filler and release control carrier.
November 2006	Received grant for joint-development theme "regeneration drug delivery systems of cartilage" with the University of Tokyo from NIBIO.
December 2006	Made Cellex K.K. our subsidiary by capital integration. Increased the capital to 424,566,000 yen.
February 2007	Applied for a patent about treatment and preventive agentfor vasospasm.
June 2007	社Altered company name to "NEXT21 K K.".
February 2008	Acquired patent as "CLOSED CELL CULTURE SYSTEM".
February 2008	Increased the capital to 574,566,000 yen by allocation of new shares to third party.

▲PAGE TOP